Insmed Announces Strong 2025 Results and Pipeline Progress

Insmed ( (INSM) ) has shared an announcement.

On January 9, 2026, Insmed reported strong preliminary unaudited 2025 financial results and pipeline progress ahead of its January 12, 2026 presentation at the J.P. Morgan Healthcare Conference, highlighted by a landmark first full year for BRINSUPRI and continued growth of ARIKAYCE. BRINSUPRI generated approximately $144.6 million in unaudited revenue in its first full quarter and $172.7 million for full-year 2025 in the U.S., with roughly 4,000 prescribers and about 9,000 new patients initiating therapy in the fourth quarter, while ARIKAYCE delivered about $433.8 million globally in 2025, exceeding guidance and driving total company revenues to approximately $606.4 million, a 67% year-on-year increase. The company outlined an aggressive 2026 roadmap, including an anticipated EU launch of BRINSUPRI following its November 2025 European Commission approval for non-cystic fibrosis bronchiectasis and planned launches in the U.K. and Japan, expected 2026 global ARIKAYCE revenues of $450 million to $470 million, and key clinical milestones: topline Phase 3 ENCORE data in MAC lung disease in March–April 2026, Phase 2b CEDAR data for brensocatib in hidradenitis suppurativa in the second quarter of 2026, initiation and expansion of multiple Phase 3 TPIP trials across PH-ILD, PAH, PPF, and IPF, and the acquisition of Phase 2–ready monoclonal antibody INS1148, collectively signaling a rapid expansion of its respiratory and inflammatory disease franchise and a potentially stronger competitive position for shareholders and patients alike.

The most recent analyst rating on (INSM) stock is a Hold with a $157.00 price target. To see the full list of analyst forecasts on Insmed stock, see the INSM Stock Forecast page.

Spark’s Take on INSM Stock

According to Spark, TipRanks’ AI Analyst, INSM is a Neutral.

Insmed’s overall stock score is primarily impacted by its financial performance challenges, including profitability and cash flow issues. While there are positive developments in product launches and regulatory approvals, these are offset by technical weaknesses and valuation concerns.

To see Spark’s full report on INSM stock, click here.

More about Insmed

Insmed Incorporated is a people-first global biopharmaceutical company focused on developing and commercializing first- and best-in-class therapies for patients with serious diseases, with a portfolio spanning respiratory, immunology and inflammation, and neuro and other rare disorders. Its key marketed products include ARIKAYCE (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease and BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, with additional pipeline programs such as treprostinil palmitil inhalation powder (TPIP) and the monoclonal antibody INS1148 targeting underserved pulmonary and inflammatory conditions.

Average Trading Volume: 2,859,025

Technical Sentiment Signal: Buy

Current Market Cap: $37.54B

Learn more about INSM stock on TipRanks’ Stock Analysis page.